More than 115 biotech companies have announced layoffs this year, on track to easily surpass 2022’s numbers. While this is not a new trend, the current trajectory is concerning, as it portends more difficult times ahead for the pharmaceutical industry–already in the midst of a major upheaval. It should also…
On August 29th, the Biden Administration named the 10 drugs that will be subject to price negotiation with Medicare in the initial implementation of the Inflation Reduction Act (IRA) of 2022. Release of the list marked a milestone in a decades-long effort by Democrats to use the purchasing power of…
For years, lawmakers have targeted the pharmaceutical industry, blaming it for the high cost of healthcare – its role in the management of Covid-19 notwithstanding. Despite recent breakthroughs to rid the world of its worst scourges, both the U.S. and EU appear to regard pharma as the single worst actor…
As our Numerof 2023 Global Pharma Outlook infographic illustrates, this year’s story for pharmaceutical manufacturers will be about continuing to adapt to pressures on price, especially mandated government negotiation, and demands for value while dealing with the long-term effects of the pandemic.
As our Numerof 2023 Global Medical Device Outlook infographic illustrates, this year’s story for medical device manufacturers will be about reconciling overhead inflation with market pressure on pricing, responding to demands for a data-based value narrative, and adjusting the commercialization process to an emerging post-pandemic reality.
Pharmaceutical executives are waking up to a hard new reality. The winds of healthcare economic change, accelerated by a historic pandemic, have upended the old “feet on the street” commercial sales playbook by which they successfully operated for good. Whether pharma leaders like it or not, the future of the…
